Vertex Pharmaceuticals, Inc.
VRTX
Market Cap$101.7B
Close$
Earnings Call Q4 2023
February 5, 2024 - AI Summary
Vertex Pharmaceuticals reported strong financial results for the fourth quarter and full year 2023, with revenue growth of 9% YoY in Q4 and 11% YoY for the full year.
The company achieved full-year CF product revenues of $9.87 billion, representing 11% growth versus 2022.
Vertex received approvals for CASGEVY, its CRISPR/Cas9-based therapy, in sickle cell disease and beta-thalassemia in multiple countries, and the launch is off to a strong start.
Exclusive for Stockcircle Pro members
Sign up
$614.75
53.4% upside
Current Fair Value
53.4% upsideUndervalued by 53.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $101.70 Billion |
|---|---|
| Enterprise Value | $90.91 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $13.89 |
| Beta | 0.71 |
| Outstanding Shares | 258,459,343 |
| Avg 30 Day Volume | 918,826 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 28.1 |
|---|---|
| PEG | 153.49 |
| Price to Sales | 10.55 |
| Price to Book Ratio | 5.89 |
| Enterprise Value to Revenue | 9.21 |
| Enterprise Value to EBIT | 21.1 |
| Enterprise Value to Net Income | 25 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
ESG Score
No data
About Vertex Pharmaceuticals, Inc.
CEO: Jeffrey Leiden